Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 06, 2015; 84 (14 Supplement) April 23, 2015

RG1662, a Selective GABAA α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. (P6.273)

Federico Bolognani, Lisa Squassante, Xavier Liogier d'Ardhuy, Maria-Clemencia Hernandez, Frederic Knoflach, Ivan Baldinotti, Jana Noeldeke, Christoph Wandel, Stephan Nave, Omar Khwaja
First published April 8, 2015,
Federico Bolognani
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Squassante
1Biostatistics F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Liogier d'Ardhuy
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria-Clemencia Hernandez
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic Knoflach
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan Baldinotti
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jana Noeldeke
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Wandel
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Nave
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar Khwaja
2Pharmaceutical Research and Early Development F.Hoffmann-La Roche AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
RG1662, a Selective GABAA α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. (P6.273)
Federico Bolognani, Lisa Squassante, Xavier Liogier d'Ardhuy, Maria-Clemencia Hernandez, Frederic Knoflach, Ivan Baldinotti, Jana Noeldeke, Christoph Wandel, Stephan Nave, Omar Khwaja
Neurology Apr 2015, 84 (14 Supplement) P6.273;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: We investigated the effect of RG1662, a GABAAα5 (GABRA5) negative allosteric modulator (NAM), on quantitative EEG (qEEG) in young adults with Down syndrome (DS). BACKGROUND: Intellectual disability associated with DS is believed to relate partly to excessive GABAergic tone. Gamma oscillations are generated by synchronization of pyramidal neurons by fast-spiking GABAergic interneurons. RG1662 is a highly selective NAM of GABA-A receptors containing the GABRA5 subunit, a target for enhancement of cognition. DESIGN/METHODS: In a randomized, double blind, placebo-controlled, multiple ascending dose study in young adults with DS aged 18-30 years, subjects received placebo, 80, 160, or 370 mg BID of RG1662 for 5 weeks (n = 8 per group). EEG recordings were obtained at baseline, day 1, and day 10. We performed a power band analysis and fit an MMRM model to the data. A classifier was also built to separate EEG features in people with DS from matched typically developing (TD) controls using PCA and an SVM algorithm. In addition, extracellular recordings in brain slices from WT and GABRA5 KO mice were used to explore GABRA5-dependency of the effects. RESULTS: There were no EEG signs of epileptiform abnormality. We observed statistically significant (p < 0.001) dose-dependent increases in gamma power after 10 days of dosing with RG1662. We were able to construct a multivariate DS index with good sensitivity and specificity (ROC AUC = 0.87). We observed a dose-dependent lowering of the DS index. Also, RG1662 modulated carbachol-induced gamma oscillations in hippocampal brain slices of WT mice, but not GABRA5 KO mice. CONCLUSIONS: GABRA5 inhibition results in clear qEEG effects in young adults with DS and may be a useful pharmacodynamic biomarker for this class of compounds. Rodent experiments suggest these effects are GABRA5-dependent. We are investigating EEG data from TD controls given multiple ascending doses of RG1662.

Disclosure: Dr. Bolognani has received personal compensation for activities with Roche as an employee. Dr. Squassante has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Liogier d'Ardhuy has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Hernandez has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Knoflach has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Baldinotti has received personal compensation for activities with Roche as an employee. Dr. Noeldeke has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Wandel has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Nave has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Khwaja has received personal compensation for activities with Roche Diagnostics Corporation as an employee.

Thursday, April 23 2015, 7:30 am-12:00 pm

  • Copyright © 2015 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise